Skip to main content

Molecular Devices Acquires Cytion for $7.5M Plus Stock

NEW YORK, July 10 – Molecular Devices has signed a definitive agreement to acquire Cytion, a Swiss developer of drug screening technology, for $7.5 million in cash and 400,000 shares of Molecular Devices stock, Molecular Devices said Tuesday.

Cytion, based in Epalinges, Switzerland, has developed a technique using automated patch clamping for analyzing ion channels, a class of proteins important as drug targets.

In addition to the upfront cash and stock payments, Molecular Devices will also make cash payments to Cytion shareholders if the company achieves certain undisclosed milestones.

Molecular Devices, a maker of systems designed to automate drug discovery tasks, said that next year the company hopes to launch its own products for performing electrophysiological research, including the study of ion channels.

"We believe that technologies for higher throughput, information-rich ion channel testing represent an important scientific innovation and a substantial market opportunity, said Joseph Keegan, CEO of Molecular Devices, in a statement. “We are very excited about the agreement to acquire Cytion, a leading developer of automated patch clamping technology that is well-positioned to address this unmet customer need.”

In April, shares of Molecular Devices plunged 58 percent after the company announced disappointing earnings.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.